[
  {
    "ts": null,
    "headline": "Senators Propose Ban on Drug Advertising to Consumers",
    "summary": "Bernie Sanders and Angus King introduced a bill that would ban pharmaceutical manufacturers from using direct-to-consumer advertising, including social media, to promote their products.",
    "url": "https://finnhub.io/api/news?id=dbd6d8a2e13d83b7439df26fb73481fa68e66753985b27c6205b80da02982329",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749757260,
      "headline": "Senators Propose Ban on Drug Advertising to Consumers",
      "id": 135223240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bernie Sanders and Angus King introduced a bill that would ban pharmaceutical manufacturers from using direct-to-consumer advertising, including social media, to promote their products.",
      "url": "https://finnhub.io/api/news?id=dbd6d8a2e13d83b7439df26fb73481fa68e66753985b27c6205b80da02982329"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Achieves FDA Approval for MAVYRET Label Expansion to Treat Pediatric Hepatitis C",
    "summary": "AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is significant as it broadens treatment options, aligning with ongoing public health goals. Over the last week, AbbVie's stock price moved up 2% amid a broader market rise of 1%. The market optimism, partly driven by overall economic data and progress in trade negotiations, may have supported AbbVie's...",
    "url": "https://finnhub.io/api/news?id=4d75c94111fb9c02423957482c1969411f1d0f6f667d7266b7d1d98ddcab576d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749750792,
      "headline": "AbbVie (NYSE:ABBV) Achieves FDA Approval for MAVYRET Label Expansion to Treat Pediatric Hepatitis C",
      "id": 135223241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is significant as it broadens treatment options, aligning with ongoing public health goals. Over the last week, AbbVie's stock price moved up 2% amid a broader market rise of 1%. The market optimism, partly driven by overall economic data and progress in trade negotiations, may have supported AbbVie's...",
      "url": "https://finnhub.io/api/news?id=4d75c94111fb9c02423957482c1969411f1d0f6f667d7266b7d1d98ddcab576d"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus",
    "summary": "NORTH CHICAGO - AbbVie announced that the U.S. Food and Drug Administration approved a label expansion for MAVYRET, an oral pangenotypic direct acting antiviral therapy.It is now approved for the...",
    "url": "https://finnhub.io/api/news?id=bf5125670f448feb683a58432e07f59a5247eafec0823271be235b95af70509f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749724080,
      "headline": "U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus",
      "id": 135212828,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO - AbbVie announced that the U.S. Food and Drug Administration approved a label expansion for MAVYRET, an oral pangenotypic direct acting antiviral therapy.It is now approved for the...",
      "url": "https://finnhub.io/api/news?id=bf5125670f448feb683a58432e07f59a5247eafec0823271be235b95af70509f"
    }
  },
  {
    "ts": null,
    "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
    "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
    "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749722400,
      "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
      "id": 135212617,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432883724/image_1432883724.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
      "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b"
    }
  }
]